Drug Profile
LY 2300559
Alternative Names: LY2300559; mGlu Pot/Cys - Eli LillyLatest Information Update: 07 Aug 2012
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antimigraines
- Mechanism of Action Leukotriene D4 receptor antagonists; Metabotropic glutamate receptor 2 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Migraine
Most Recent Events
- 16 Jul 2012 Discontinued - Phase-II for Migraine in Puerto Rico (PO)
- 16 Jul 2012 Discontinued - Phase-II for Migraine in USA (PO)
- 01 Apr 2012 Eli Lilly completes a phase II trial for Migraine prevention in USA and Puerto Rico (NCT01184508)